Zimmer Biomet Holdings, Inc. (VIE:ZBH)
Austria
· Delayed Price · Currency is EUR | Market Cap | 15.28B |
| Revenue (ttm) | 7.29B |
| Net Income (ttm) | 660.19M |
| Shares Out | n/a |
| EPS (ttm) | 3.34 |
| PE Ratio | 23.14 |
| Forward PE | 10.66 |
| Dividend | 0.82 (1.07%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | n/a |
| Average Volume | 7 |
| Open | 79.22 |
| Previous Close | 79.24 |
| Day's Range | 77.30 - 81.34 |
| 52-Week Range | 71.50 - 92.86 |
| Beta | n/a |
| RSI | 31.28 |
| Earnings Date | Apr 28, 2026 |
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well a... [Read more]
Financial Performance
In 2025, Zimmer Biomet Holdings's revenue was $8.23 billion, an increase of 7.20% compared to the previous year's $7.68 billion. Earnings were $705.10 million, a decrease of -21.98%.
Financial numbers in USDNews
Tariffs Benefit, CFO Exit: What's Going On With Zimmer Biomet Stock On Tuesday?
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported first-quarter adjusted earnings of $2.09 per share, up 15.5% year over year, beating the Street estimates of $1.86.
Zimmer Biomet Holdings Earnings Call Transcript: Q1 2026
Sales grew 2.9% organically, with adjusted EPS up 15% year-over-year and strong technology adoption. Guidance for revenue growth and margins is unchanged, but EPS and free cash flow outlooks were raised. Strategic investments and sales force transformation continue to drive momentum.
Medical device maker Zimmer Biomet raises annual profit forecast, announces CFO departure
Zimmer Biomet on Tuesday raised its 2026 adjusted profit forecast after reporting better-than-expected quarterly results, helped by strong demand for its medical devices and new product launches.
Zimmer Biomet Announces First Quarter 2026 Financial Results
First quarter net sales of $2.087 billion increased 9.3% on a reported basis, 6.8% on a constant currency1 basis and 2.9% on an organic constant currency1 basis First quarter diluted earnings per shar...
Zimmer Biomet Announces Chief Financial Officer Transition
Suketu Upadhyay to Depart; Paul Stellato Named Interim CFO WARSAW, Ind., April 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today anno...
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results
WARSAW, Ind., April 9, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its first quarter earnings conference call will be web...
Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer
Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacity WARSAW, Ind., April 7, 2026 /PRNewswir...
Zimmer Biomet Holdings, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zimmer Biomet Holdings, Inc., (“Zimmer" or the "Company") (NYSE:ZBH) investors that the firm has initiated an investigation...
Zimmer Biomet to Release New Data, Highlight Key Innovations at American Academy of Orthopaedic Surgeons Annual Meeting
Company's Chief Movement Officer, Arnold Schwarzenegger,Will Be Presidential Guest Speaker WARSAW, Ind., Feb. 25, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medica...
Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2026
WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment o...
Zimmer Biomet Holdings Earnings Call Transcript: Q4 2025
Q4 2025 saw 5.4% organic sales growth and strong U.S. performance, with new products and robotics driving results. 2026 guidance anticipates 1%-3% revenue growth and continued Salesforce transformation, with short-term disruption but long-term productivity gains expected.
Zimmer Biomet beats quarterly estimates on strong hips, knees device demand
Zimmer Biomet on Tuesday beat Wall Street estimates for fourth-quarter profit and revenue as the company capitalized on steady demand for its devices used in orthopedic procedures.
Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results
Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basis Fourth quarter diluted earnings per s...
Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2025 Financial Results
WARSAW, Ind., Jan. 15, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its fourth quarter earnings conference call will be we...
Zimmer Biomet Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
The event highlighted a five-year transformation with strong growth, a shift to customer-centric innovation, and a major overhaul of the U.S. sales model. Key product launches and investments in robotics and ASCs are set to drive future growth, with tempered 2026 guidance reflecting ongoing transformation.
Zimmer Biomet to Present at the 44th Annual J.P. Morgan Healthcare Conference
WARSAW, Ind. , Dec. 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team wil...
Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2025
WARSAW, Ind., Dec. 17, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment o...
Zimmer Biomet, OneStep Collaborate to Provide Enhanced Mobility Data to Patients and Surgeons to Help Improve Joint Procedure Recovery
OneStep's Clinically Validated Mobility Intelligence Technology to Integrate into Zimmer Biomet's mymobility® Care Management Platform to Further Enhance Recovery Monitoring WARSAW, Ind., Dec. 16, 202...
Zimmer Biomet Holdings (ZBH) Faces Investor Scrutiny Amid Emerging Markets Distributor Orders Cancelation, Reduced Top-Line Revenue Forecast -- Hagens Berman
SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- On November 5, 2025, investors in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) saw the price of their shares tumble $15.63 (-15%) after the company announc...
Bragar Eagel & Squire, P.C. Is Investigating Gauzy and Zimmer Biomet and Encourages Investors to Contact the Firm
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Gauzy Ltd. (NASDAQ:GAUZ) and Z...
Zimmer Biomet Holdings Transcript: Jefferies London Healthcare Conference 2025
Healthy orthopedic markets and robust innovation are driving growth, with new technologies like anti-infective implants and autonomous robotics set for launch in 2026-2027. Operational improvements and a focus on U.S. performance are expected to support margin expansion and consistent execution.
Could Zimmer Biomet Stock Be Your Next Buy?
Zimmer Biomet (ZBH) could be a strong choice for your investment portfolio, due to its high cash yield, solid fundamentals, and discounted valuation. Companies like this have the capacity to leverage ...
Zimmer Biomet Receives U.S. FDA Clearance for Enhanced Version of ROSA® Knee Robotic Technology
ROSA ® Knee with OptimiZe ™ Offers Personalized Surgical Planning and Drives Confidence in Delivering Accurate and Reproducible Outcomes1 WARSAW, Ind., Nov. 14, 2025 /PRNewswire/ -- Zimmer Biomet Hold...
Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London
WARSAW, Ind., Nov. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will ...
Time To Buy Zimmer Biomet Stock?
Zimmer Biomet (ZBH) stock ought to be on your radar. Here's why – it is presently trading within the support range ($83.17 – $91.93), levels from which it has rebounded significantly in the past.